Inflammatory bowel diseases
Cure8 research brief
Why This Matters
This large US claims study compares safety outcomes (serious infections, heart attacks/stroke, and venous clots) for tofacitinib versus multiple biologic therapies in people with ulcerative colitis — questions many patients and clinicians have when weighing treatment options.
Who Should Pay Attention
Adults with ulcerative colitis considering or taking tofacitinib or biologic therapies, clinicians managing UC treatment choices, and researchers studying treatment safety.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This abstract reports an observational claims-database study comparing risks of serious infections, myocardial infarction/stroke, and venous thromboembolism in US patients with ulcerative colitis who started tofacitinib versus several biologic therapies (ustekinumab, vedolizumab, and tumor necrosis factor inhibitors) between 2018 and 2022.
The authors used propensity weighting and Cox models and found no significant differences in the risk of serious infections, MI/stroke, or VTE between tofacitinib and the biologics in this dataset. The patient groups differed at baseline: more patients starting tofacitinib had prior biologic exposure, which the authors adjusted for statistically.
The study uses real-world insurance claims data, which captures large patient numbers but can lack clinical detail compared with randomized trials.
If you take or are considering these treatments, this study adds to safety data by reporting similar rates of the examined adverse events across drugs in this claims cohort, but it does not replace individualized medical advice or regulatory safety guidance.
Keep In Mind
This record is an abstract of an observational study using insurance claims (Komodo Health). Claims data enable large sample sizes but can miss clinical details and are subject to residual confounding despite statistical adjustment. The abstract reports no significant differences but does not present full paper-level details in this extract.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationInflammatory bowel diseases
AuthorsDavid T Rubin, Stefan Schreiber, Laurent Peyrin-Biroulet +12 more
InstitutionUniversity of Chicago Medicine Inflammatory Bowel Disease Center, Chicago, IL 60637, United States.
Study typeJournal article
Indexed viaPubMed
Source typeResearch paper
PublishedJul 28, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Upadacitinib Reduces Rates of Hospitalization in Ulcerative Colitis: A Large-Scale Nationwide Cohort Study
Lower hospitalization rates suggest upadacitinib may reduce severe disease events that require inpatient care, which matters to patients and clinicians aiming to avoid hospital stays and complications. Large real-world...
Methotrexate for inflammatory bowel disease: the MICI-METHO multicenter retrospective cohort study.
Methotrexate is commonly used in IBD, often with biologics, but real‑world data on how long patients stay on it, typical dosing, and safety in large contemporary cohorts are limited.
Ustekinumab Has Better Cardiovascular Safety Than Vedolizumab in IBD Management
Older adults with IBD have higher cardiovascular risk; medication choice may affect cardiovascular outcomes. This study suggests ustekinumab users had fewer deaths and some cardiac events than vedolizumab users, which...